Neumora Therapeutics, Inc. Common Stock
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The company applies a precision medicine approach that combines neuroscience, biological insight, and data science to identify and advance therapies aimed at central nervous system targets. Its current pipeline includes candidate medicines in clinical and preclinical development for major depressive disorder, agitation associated with dementia, schizophrenia, Parkinson’s disease, ALS, and obesity-related metabolic disease. Neumora Therapeutics is positioned within the biotechnology sector as a research-driven company centered on novel mechanisms of action for underserved neurological and psychiatric disorders. The common stock reflects the market’s view of a company whose value is tied to progress across this specialized drug development pipeline and the broader demand for new CNS therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Joshua Pinto Ph.D.
- Employees
- 63
- Headquarters
- Watertown, MA, United States
- Website
- www.neumoratx.com